Examkin

Question

Difficulty: MediumMedical Literature and Drug Advertisement Interpretation

A 68-year-old man with a history of myocardial infarction and heart failure with reduced ejection fraction comes to the clinic for a routine follow-up. He brings a magazine advertisement for a newly approved medication, Myocordin, which claims to "reduce the risk of major cardiovascular events by 25%." The patient is very interested in taking this medication, specifically asking, "Will this drug help me live longer and prevent another heart attack?"

The clinician examines the full text of the pivotal trial cited in the promotional material. The study evaluated a primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure. The results for the primary composite endpoint and its individual components are presented in the following table:

OutcomeHazard Ratio95% Confidence Interval
Primary composite endpoint0.750.750.66−0.850.66 - 0.85
Cardiovascular death0.920.920.78−1.080.78 - 1.08
Nonfatal myocardial infarction0.950.950.81−1.110.81 - 1.11
Hospitalization for heart failure0.600.600.51−0.700.51 - 0.70

Based on the trial data, which of the following is the most appropriate response regarding the patient's specific question?

  1. The significant benefit reported in the study is driven by fewer hospitalizations for heart failure, rather than improved survival.Answer
  2. B
    The medication significantly reduces your risk of both cardiovascular death and recurrent myocardial infarction.
  3. C
    The medication decreases your risk of mortality, but this effect is likely confounded by your baseline heart failure status.
  4. D
    The medication is contraindicated for you because the confidence intervals suggest a potential for increased cardiovascular death.
  5. E
    The medication should be initiated cautiously to avoid pharmacokinetic interactions with your current heart failure medications.

Answer

The significant benefit reported in the study is driven by fewer hospitalizations for heart failure, rather than improved survival.
The correct response accurately reflects the data presented in the trial table. A composite endpoint combines multiple clinical outcomes into a single primary endpoint to increase statistical power. In this trial, the overall composite endpoint is statistically significant (Hazard Ratio 0.750.75, 95% CI 0.66−0.850.66 - 0.85, which does not cross 1.01.0). However, when examining the individual components, only 'hospitalization for heart failure' is statistically significant (HR 0.600.60, 95% CI 0.51−0.700.51 - 0.70). The confidence intervals for both 'cardiovascular death' (0.78−1.080.78 - 1.08) and 'nonfatal myocardial infarction' (0.81−1.110.81 - 1.11) cross 1.01.0. This means there is no statistically significant evidence that the medication reduces mortality or prevents heart attacks. Therefore, the overall benefit claimed in the advertisement is driven almost entirely by the reduction in heart failure hospitalizations.

Step-by-Step Solution

1
Analyze the primary composite endpoint result.
The Hazard Ratio is 0.750.75 with a 95% CI of 0.66−0.850.66 - 0.85.
To determine if the overall study demonstrated a statistically significant benefit (which it did, as the CI does not cross 1.01.0).
2
Evaluate the individual components of the composite endpoint.
Cardiovascular death CI (0.78−1.080.78 - 1.08) and nonfatal MI CI (0.81−1.110.81 - 1.11) both cross 1.01.0. Hospitalization for heart failure CI (0.51−0.700.51 - 0.70) does not cross 1.01.0.
To accurately answer the patient's specific question about living longer and preventing heart attacks.
3
Synthesize the findings to formulate an appropriate patient response.
The medication reduces heart failure hospitalizations but does not definitively reduce mortality or myocardial infarction risk.
The statistical significance of the composite endpoint is driven entirely by the hospitalization component.

Key Concept

When evaluating a composite endpoint in clinical trials, a statistically significant overall result may be driven by a single, often less clinically severe component (e.g., hospitalization) rather than hard clinical outcomes like mortality or myocardial infarction.
Rate this question

Topics

Medical Literature and Drug Advertisement Interpretation

More questions from this topic